share_log

D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $12 Price Target

Benzinga ·  Nov 13, 2024 01:39  · Ratings

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:QNCX) with a Buy and maintains $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment